Possibia

912938

Last Update Posted: 2010-02-17

Recruiting status is unknown

Females

accepted

18 Years +

237 Estimated Participants

No Expanded Access

Interventional Study

Does not accept healthy volunteers

Evaluate the Relationship of Bone Remodeling Markers for Skeletal Complications in Metastatic Breast Cancer Patients

to evaluate whether bone marker can provide the valuable predictor of skeletal complications and whether regular assessing of NTX(N-telopeptide of type I collagen) and osteocalcin can be useful in advanced breast cancer patients with bone metastasis receiving zoledronic acid.

to evaluate the efficacy and safety of zoledronic acid by measuring changes in bone turnover markers

  • the incidence of skeletal-related events
  • time to skeletal-related events
  • time to bone metastases progression
  • overall survival
  • the incidence of each adverse event including osteonecrosis

Eligibility

Relevant conditions:

Metastatic Breast Cancer

If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.

locations

Contact Information

Overall Contact

No valid contacts available

Data sourced from ClinicalTrials.gov